Systemic, vascular diseases and ageing

Antoni Riera Mestre

PRINCIPAL INVESTIGATORS
  • Mª Jose Castro Castro
  • Francesc Formiga Perez
  • Ramon Lleonart Bellfill
  • Eloi Montañez Miralles
  • Javier Pinto Sala
  • Xavier Solanich Moreno
  • Pilar Villacampa Alcubierre
CLINICAL RESEARCHERS
  • Blanca Andres Lopez
  • Arnau Antoli Gil
  • Olga Capdevila Pons
  • David Chivite Guillen
  • Ana Contra i Carné
  • Virginia Esteve Luque
  • Marta Gloria Fanlo Maresma
  • Enric Gamundí Grimalt
  • Aimar Guillen Blanquez
  • Adriana Iriarte Fuster
  • Francesca Mitjavila Villero
  • Abelardo Montero Saez
  • Gemma Rocamora Blanch
    Alba Sanz Alcala
  • Raquel Torres Iglesias
  • Ferran Trias Vilagut
  • Paula Vazquez Revuelta
POSTDOCTORAL RESEARCHERS
  • Bárbara Fernández Cidón
PREDOCTORAL RESEARCHERS
  • Silvia Cardona Piñeiro
  • Anna Casellas Bernades
  • Ana Galera Cusi
  • Hannia Elena Lafuente Gonzalez
  • Nekane Maritorena Hualde
  • Queralt Ordi Camprubi
  • Jose Luis Rocamora Navarro
  • Maria Angeles Rodriguez Sanchez
  • Maria Iciar Sarasa Corral
  • Bernat Villanueva Cutillas
SCIENTIFIC SUPPORT
  • Emili Corbella Ingles
  • Jose Luis Gomez Vazquez
  • Angels Sierra Fortuny
Translational Medicine
Cardiovascular, Respiratory and Systemic Diseases and cellular aging

Scientific production

57

PAPERS

Average IF: 6,46

10

LED PAPERS

Average IF: 3,61

12 PUBLICATIONS IN FIRST DECILE

33 PUBLICATIONS IN FIRST QUARTILE

39 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Al Samkari,H;Hessels,J;Riera Mestre,A;Dupuis Girod,S;Van Zele,T;del Olmo,VG;Hodges,PG et al, Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia, N Engl J Med, 2025;393(21):2131-2141, doi:10.1056/NEJMoa2504411
  • Yun,S;Comín Colet,J;Calero Molina,E;Hidalgo,E;José Bazán,N;Cobo Marcos,M;Soria,T et al, Evaluation of mobile health technology combining telemonitoring and teleintervention versus usual care in vulnerable-phase heart failure management (HERMeS): a multicentre, randomised controlled trial., Lancet Digit Health, 2025;7(5):100866-100866, doi:10.1016/j.landig.2025.02.006
  • Ruiz Canela,M;Corella,D;Martinez Gonzalez,MA;Babio,N;Martinez,JA;Forga,L;Alonso Gomez,AM et al, Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes A Secondary Analysis of a Randomized Controlled Trial, Ann Intern Med, 2025;178(10):1378-1389, doi:10.7326/ANNALS-25-00388
  • Sánchez Vera,I;Cosialls,AM;Maritorena Hualde,N;Schuler,MH;Lavilla,R;Pons,G;Jae,LT et al, Targeting prohibitins activates the ISR through DELE1-HRI by impairing protein import into the mitochondrial matrix., Cell Death Differ, 2025;doi:10.1038/s41418-025-01618-0
  • Pandey,A;Segar,MW;Keshvani,N;Llácer,P;Casado,J;Morales Rull,JL;Formiga,F et al, Diuretic resistance and the efficacy of hydrochlorothiazide in acute decompensated heart failure: A post-hoc analysis of the CLOROTIC trial., Eur J Heart Fail, 2025;27(12):3142-3150, doi:10.1002/ejhf.70002

Research highlights

PROJECTS

8 Ongoing competitive projects

9 Stated clinical trials
26 Ongoing clinical trials

PUBLISHED WORKS

45 Clinical Guidelines
1 Thesis

NETWORKS

COVID-HGE
RIETE
RiHHTa
CIBEROBN
AGAUR SGR GRC 2021

Selected projects

  • J3L-MC-EZEF. Estudio de fase 3, aleatorizado, con enmascaramiento doble, comparativo con un placebo, para investigar el efecto de Lepodisirán sobre la reducción de los acontecimientos cardiovasculares adversos graves en adultos que presenten elevación de la lipoproteína(a) y enfermedad cardiovascular ateroesclerótica confirmada o riesgo de sufrir un primer acontecimiento cardiovascular – ACCLAIM-LP (A). Eli Lilly and Company. Budget: 514.320€. 2024- . PI: JAVIER PINTO SALA.
  • ALN-6400-001. A Phase 1/2, Randomized, Double-blind, Placebo-controlled,2-part Study of the Safety, Tolerability, Efficacy,Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and Multiple Dose ALN-6400 in Adult Patients with Hereditary Hemorrhagic Telangiectasia (HHT).. ALNYLAM PHARMACEUTICALS, INC. Budget: 288.959,4€. 2025- . PI: ANTONI RIERA MESTRE.
  • CTQJ230A12301E1. A single arm, multicenter, open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants who completed the parent Lp(a)HORIZON trial.l. NOVARTIS PHARMA AG. Budget: 191.565€. 2026- . PI: JAVIER PINTO SALA.
  • MK-0616-015. ESTUDIO DE FASE 3, ALEATORIZADO Y CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE MK-0616 PARA REDUCIR LAS COMPLICACIONES CARDIOVASCULARES GRAVES EN PARTICIPANTES CON RIESGO CARDIOVASCULAR ELEVADO. MERCK SHARP & DOHME LLC. Budget: 184.110€. 2024- . PI: JAVIER PINTO SALA.
  • PREDIGA. MEMORIA PARA EL ESTUDIO DE ESPLENOMEGALIA Y PACIENTES ESPLENECTOMIZADOS NO FILIADOS EN POBLACIÓN INFANTIL Y ADULTA. Fundación Española de Hematología y Hemoterapia FEHH. Budget: 134.000€. 2020- . PI: XAVIER SOLANICH MORENO.